Literature DB >> 9256273

Inhibition of the alloantibody response by CD95 ligand.

H Arai1, S Y Chan, D K Bishop, G J Nabel.   

Abstract

We investigated the effect of Fas/APO1-ligand (CD95L) gene transfer on allogeneic immune responses in vivo. A colon carcinoma cell line from BALB/c mice, CT26, was stably transfected with a vector encoding mouse CD95L and was inoculated into C57BL/6 mice. CD95L expression markedly reduced allogeneic cytotoxic T lymphocyte and helper T lymphocyte activity directed toward CT26. Strikingly, expression of CD95L on these allogeneic tumors completely inhibited the generation of alloantibodies of both IgM and IgG subclasses. Thus, CD95L inhibited alloantibody production and conferred localized immune suppression through this mechanism. These results provide insight into the role of CD95L in regulating the alloantibody response and the generation of local immune responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256273     DOI: 10.1038/nm0897-843

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  16 in total

1.  CD95 ligand expression as a mechanism of immune escape in breast cancer.

Authors:  M Müschen; C Moers; U Warskulat; J Even; D Niederacher; M W Beckmann
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 2.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

3.  Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.

Authors:  Esma S Yolcu; Hong Zhao; Laura Bandura-Morgan; Chantale Lacelle; Kyle B Woodward; Nadir Askenasy; Haval Shirwan
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

Review 4.  Fas (CD95, Apo-1) ligand gene transfer.

Authors:  S E Lamhamedi-Cherradi; Y Chen
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

5.  Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.

Authors:  Wei Zhang; Er-Xun Ding; Qiang Wang; Da-Qiao Zhu; Jin He; Yu-Li Li; Yuan-He Wang
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

6.  Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.

Authors:  M W Bennett; J O'connell; G C O'sullivan; D Roche; C Brady; J Kelly; J K Collins; F Shanahan
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

7.  Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J O'Callaghan; J K Collins; F Shanahan
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

8.  Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids.

Authors:  A Lepple-Wienhues; C Belka; T Laun; A Jekle; B Walter; U Wieland; M Welz; L Heil; J Kun; G Busch; M Weller; M Bamberg; E Gulbins; F Lang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

9.  Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein.

Authors:  Esma S Yolcu; Xiao Gu; Chantale Lacelle; Hong Zhao; Laura Bandura-Morgan; Nadir Askenasy; Haval Shirwan
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

10.  Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival.

Authors:  Gaosi Xu; Jiangguo Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.